INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 432m ago
HOUSE PTR32m ago
SEC 13F31m ago
ROBINHOOD CHAIN31m ago
SEC FORM 4/Option exerciseVerified data

Piekos Brian reported KALV

Chief Financial Officer · KalVista Pharmaceuticals, Inc. · KalVista Pharmaceuticals, Inc. — Restricted Stock Unit

Side
M
Value
—
Shares
6,250
Price
—
Executed
Apr 16, 2026
Disclosed
Apr 20, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Apr 16 executedApr 20, 2026 disclosed

KALV · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+5 / 25

No reported dollar value · 7.1% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · KALV

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    TP
    Treanor PatrickDirector
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    17.0K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    5
    SN
    Sweeny NicoleChief Commercial Officer
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    40.0K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    5
    SN
    Sweeny NicoleChief Commercial Officer
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    59.3K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    5
    SN
    Sweeny NicoleChief Commercial Officer
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    100.0K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    5
    SN
    Sweeny NicoleChief Commercial Officer
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    93.8K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    5
    PB
    Piekos BrianChief Financial Officer
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    55.0K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    5
    PB
    Piekos BrianChief Financial Officer
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    93.8K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    5
    AK
    Audhya Paul K.CHIEF MEDICAL OFFICER
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    150.3K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    9
    AB
    Arif BilalChief Operations Officer
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    49.0K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    5
    PB
    Piekos BrianChief Financial Officer
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    21.7K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    5
    SN
    Sweeny NicoleChief Commercial Officer
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    68.8K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    5
    AK
    Audhya Paul K.CHIEF MEDICAL OFFICER
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    25.8K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    5
    PB
    Piekos BrianChief Financial Officer
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    100.0K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    9
    TP
    Treanor PatrickDirector
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    10.0K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    9
    AB
    Arif BilalChief Operations Officer
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    100.0K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    9
    TP
    Treanor PatrickDirector
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    10.0K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    9
    TP
    Treanor PatrickDirector
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    30.0K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    9
    SB
    Sensenig BethanyDirector
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    45.0K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    5
    AK
    Audhya Paul K.CHIEF MEDICAL OFFICER
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    100.0K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    5
    AK
    Audhya Paul K.CHIEF MEDICAL OFFICER
    KALVKalVista Pharmaceuticals, Inc.
    Disposition to issuer
    		D—
    40.0K sh
    		Jun 11, 2026Jun 11, 2026
    traded Jun 11, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001815308-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Apr 16, 2026
    Published
    Apr 20, 2026
    Ingested by INSIDER
    Nov 5, 04:03 UTC
    Last re-read
    Nov 5, 04:03 UTC

    Extracted facts

    Filer
    Piekos Brian
    Role
    Chief Financial Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    KalVista Pharmaceuticals, Inc. — Restricted Stock Unit
    Ticker
    KALV
    Shares
    6,250
    Price per share
    $0
    Execution date (reported)
    Apr 16, 2026
    Owned after transaction
    93.8K shares
    Days from execution to publication
    4

    What this establishes

    Piekos Brian filed this Form 4 reporting a option exercise of KALV on Apr 16, 2026. It became public on Apr 20, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Piekos Briancik:0001815308
    Issuer
    KalVista Pharmaceuticals, Inc.cik:0001348911

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.